A role for PFKFB3/iPFK2 in metformin suppression of adipocyte inflammatory responses

Journal of Molecular Endocrinology

Volumn 59, Issue 1, 2017, Pages 49-59

  Qi, Ting ^a   Chen, Yanming ^b   Li, Honggui ^a   Pei, Ya ^a   Woo, Shih Lung ^a   Guo, Xin ^a   Zhao, Jiajia ^a   Qian, Xiaoxian ^b   Awika, Joseph ^a   Huo, Yuqing ^c,d   Wu, Chaodong ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d PEKING UNIVERSITY   (China)

Author keywords

Adipocyte; Inducible 6 phosphofructo 2 kinase; Inflammatory responses; Metformin; Obesity

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE FRUCTOSE 2,6 BISPHOSPHATASE; FRUCTOSE 2,6 BISPHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; METFORMIN; PROTEIN P46; STRESS ACTIVATED PROTEIN KINASE P46; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 6 PHOSPHOFRUCTO 2 KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IL1B PROTEIN, MOUSE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NONSTEROID ANTIINFLAMMATORY AGENT; PFKFB3 PROTEIN, MOUSE;

3T3-L1 CELL LINE; ADIPOCYTE; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; INFLAMMATION; INSULIN SIGNALING; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MOUSE; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ADIPOCYTES; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MAP KINASE KINASE 4; METFORMIN; MICE; PHOSPHOFRUCTOKINASE-2; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85042164343     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-17-0066     Document Type: Article

References (43)

1. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, Pillot B, Bado A, Tronche F, Mithieux G, et al. 2006 Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147 2432–2441. (doi:10.1210/en.2005-0898)
2. Anthony J, Kelkar A, Wilankar C, Ranjith V, Bhumra SK, Mutt S, Deka N, Sivaramakrishnan H, Sharma S & Marita AR 2013 Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS ONE 8 e77946. (doi:10.1371/journal.pone.0077946)
3. Berg AH, Combs TP, Du X, Brownlee M & Scherer PE 2001 The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7 947–953. (doi:10.1038/90992)
4. Boyle JG, Logan PJ, Jones GC, Small M, Sattar N, Connell JMC, Cleland SJ & Salt IP 2011 AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia 54 1799–1809. (doi:10.1007/s00125-011-2126-4)
5. Cheung AT, Wang J, Ree D, Kolls JK & Bryer-Ash M 2000 Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 49 810–819. (doi:10.2337/diabetes.49.5.810)
6. Collier CA, Bruce CR, Smith AC, Lopaschuk G & Dyck DJ 2006 Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. American Journal of Physiology: Endocrinology and Metabolism 291 E182–E189. (doi:10.1152/ajpendo.00272.2005)
7. Daval M, Diot-Dupuy F, Bazin R, Hainault I, Viollet BT, Vaulont S, Hajduch E, Ferré P & Foufelle F 2005 Anti-lipolytic action of AMP- activated protein kinase in rodent adipocytes. Journal of Biological Chemistry 280 25250–25257. (doi:10.1074/jbc.M414222200)
8. Greenberg AS & Obin MS 2006 Obesity and the role of adipose tissue in inflammation and metabolism. American Journal of Clinical Nutrition 83 461S–465S.
9. Guo X, Li H, Xu H, Halim V, Thomas LN, Woo S-L, Huo Y, Chen YE, Sturino JM & Wu C 2013 Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response. Journal of Nutritional Biochemistry 24 770–775. (doi:10.1016/j.jnutbio.2012.04.007)
10. Guo X, Li H, Xu H, Halim V, Zhang W, Wang H, Ong KT, Woo SL, Walzem RL, Mashek DG, et al. 2012 Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. PLoS ONE 7 e39286. (doi:10.1371/annotation/f6ebe3d3-ef7c-42ce-86fe-d5a661d7f67f)
11. Guo X, Xu K, Zhang J, Li H, Zhang W, Wang H, Lange AJ, Chen YE, Huo Y & Wu C 2010 Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of PPARγ activation in mice. Journal of Biological Chemistry 285 23711–23720. (doi:10.1074/jbc. M110.123174)
12. Heishi M, Ichihara J, Teramoto R, Itakura Y, Hayashi K, Ishikawa H, Gomi H, Sakai J, Kanaoka M, Taiji M, et al. 2006 Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin. Diabetologia 49 1647–1655. (doi:10.1007/s00125-006-0271-y)
13. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF & Spiegelman BM 1996 IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271 665–668. (doi:10.1126/science.271.5249.665)
14. Huo Y, Guo X, Li H, Wang H, Zhang W, Wang Y, Zhou H, Gao Z, Telang S, Chesney J, et al. 2010 Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response. Journal of Biological Chemistry 285 3713–3721. (doi:10.1074/jbc. M109.058446)
15. Huo Y, Guo X, Li H, Xu H, Halim V, Zhang W, Wang H, Fan Y-Y, Ong KT, Woo S-L, et al. 2012 Targeted overexpression of inducible 6-phosphofructo-2-kinase in adipose tissue increases fat deposition but protects against diet-induced insulin resistance and inflammatory responses. Journal of Biological Chemistry 287 21492–21500. (doi:10.1074/jbc.M112.370379)
16. Huypens P, Quartier E, Pipeleers D & Van de Casteele M 2005 Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. European Journal of Pharmacology 518 90–95. (doi:10.1016/j. ejphar.2005.06.016)
17. Jelenik T, Rossmeisl M, Kuda O, Jilkova ZM, Medrikova D, Kus V, Hensler M, Janovska P, Miksik I, Baranowski M, et al. 2010 AMP-activated protein kinase 2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids. Diabetes 59 2737–2746. (doi:10.2337/db09-1716)
18. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK & Bergman RN 2005 Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. American Journal of Physiology: Endocrinology and Metabolism 288 E454–E461. (doi:10.1152/ajpendo.00203.2004)
19. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, et al. 2006 Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. Journal of Biological Chemistry 281 26602–26614. (doi:10.1074/jbc. M601284200)
20. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B & Lee C-H 2008 Adipocyte-derived Th2 cytokines and myeloid PPARδ regulate macrophage polarization and insulin sensitivity. Cell Metabolism 7 485–495. (doi:10.1016/j.cmet.2008.04.002)
21. Kim H-J, Higashimori T, Park S-Y, Choi H, Dong J, Kim Y-J, Noh H-L, Cho Y-R, Cline G, Kim Y-B, et al. 2004 Differential effects of interleukin-6 and-10 on skeletal muscle and liver insulin action in vivo. Diabetes 53 1060–1067. (doi:10.2337/diabetes.53.4.1060)
22. Lu C-H, Hung Y-J & Hsieh P-S 2016 Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. European Journal of Pharmacology 789 60–67. (doi:10.1016/j.ejphar.2016.07.012)
23. Lumeng CN, DeYoung SM, Bodzin JL & Saltiel AR 2007 Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56 16–23. (doi:10.2337/db06-1076)
24. Mendoza EE, Pocceschi MG, Kong X, Leeper DB, Caro J, Limesand KH & Burd R 2012 Control of glycolytic flux by AMP-activated protein kinase in tumor cells adapted to low pH. Translational Oncology 5 208–216. (doi:10.1593/tlo.11319)
25. Okar DA, Wu C & Lange AJ 2004 Regulation of the regulatory enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphate. In Advances in Enzyme Regulation, pp 123–154: Elsevier.
26. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P & Bolli GB 1994 Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43 920–928. (doi:10.2337/diab.43.7.920)
27. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG & Hue L 2004 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochemical Journal 381 561–579. (doi:10.1042/BJ20040752)
28. Shin N-R, Lee J-C, Lee H-Y, Kim M-S, Whon TW, Lee M-S & Bae J-W 2013 An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63 727–735. (doi:10.1136/gutjnl-2012-303839)
29. Shoelson SE, Herrero L & Naaz A 2007 Obesity, inflammation, and insulin resistance. Gastroenterology 132 2169–2180. (doi:10.1053/j. gastro.2007.03.059)
30. Song S, Andrikopoulos S, Filippis C, Thorburn AW, Khan D & Proietto J 2001 Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin. American Journal of Physiology: Endocrinology and Metabolism 281 E275–E282. (doi:10.1371/journal.pone.0112699)
31. Steinberg GR, Michell BJ, van Denderen BJW, Watt MJ, Carey AL, Fam BC, Andrikopoulos S, Proietto J, Görgün CZ, Carling D, et al. 2006 Tumor necrosis factor [alpha]-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metabolism 4 465–474. (doi:10.1016/j.cmet.2006.11.005)
32. Stumvoll M, Nurjhan N, Perriello G, Dailey G & Gerich JE 1995 Metabolic effects of metformin in non-insulin dependant diabetes mellitus. New England Journal of Medicine 333 550–554. (doi:10.1056/NEJM199508313330903)
33. Trujillo ME & Scherer PE 2006 Adipose tissue-derived factors: impact on health and disease. Endocrine Reviews 27 762–778. (doi:10.1210/er.2006-0033)
34. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL & Ferrante AWJ 2003 Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigtion 112 1796–1808. (doi:10.1172/JCI200319246)
35. Woo S-L, Xu H, Li H, Zhao Y, Hu X, Zhao J, Guo X, Guo T, Botchlett R, Qi T, et al. 2014 Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS ONE 9 e91111. (doi.org/10.1371/journal.pone.0091111)
36. Wu C, Kang JE, Peng L, Li H, Khan SA, Hillard CJ, Okar DA & Lange AJ 2005a Enhancing hepatic glycolysis reduces obesity: Differential effects on lipogenesis depend on site of glycolytic modulation. Cell Metabolism 2 131–140. (doi:10.1016/j.cmet.2005.07.003)
37. Wu C, Okar DA, Kang J & Lange AJ 2005b Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Current Drug Targets: Immune Endocrine & Metabolic Disorders 5 51–59. (doi:10.2174/1568008053174769)
38. Wu C, Khan SA, Peng LJ, Li H, Camela S & Lange AJ 2006 Perturbation of glucose flux in the liver by decreasing fructose-2,6-bisphosphate levels causes hepatic insulin resistance and hyperglycemia. American Journal of Physiology: Endocrinology and Metabolism 291 E536–E543. (doi:10.1152/ajpendo.00126.2006)
39. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, et al. 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigtion 112 1821–1830. (doi:10.1172/JCI200319451)
40. Ye J, Gao Z, Yin J & He Q 2007 Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. American Journal of Physiology: Endocrinology and Metabolism 293 E1118–E1128. (doi:10.1152/ajpendo.00435.2007)
41. Zhao W, Li A, Feng X, Hou T, Liu K, Liu B & Zhang N 2016 Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell Signal 28 1401–1411. (doi:10.1016/j.cellsig.2016.06.018)
42. Zheng J, Woo S-L, Hu X, Botchlett R, Chen L, Huo Y & Wu C 2015 Metformin and metabolic diseases: a focus on hepatic aspects. Frontiers in Medicine 9 1–14. (doi:10.1007/s11684-015-0384-0)
43. Zulian A, Cancello R, Girola A, Gilardini L, Alberti L, Croci M, Micheletto G, Danelli P & Invitti C 2011 In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obesity Facts 4 27–33. (doi:10.1159/000324582)